Applicants must be a faculty member from UCSF, UC Berkeley, or the University of Washington. Principal investigators (PI) may submit separate and distinct proposals to both funding categories listed above, however a PI is only eligible to receive one award.

Note: Current ATN Investigators are not eligible to apply through this RFP for additional funds for a previously funded award; no sub-awarding allowed. Affiliates are not eligible to apply, a PI’s PRIMARY appointment must be with UCSF, UC Berkeley, or University of Washington.

Disease Areas | Include, but not limited to the following:

• Alzheimer’s Disease: potential focus areas include neuroinflammation, peripheral immune cross-talk, and lipid metabolism

• Parkinson’s Disease: potential focus areas include lysosomal biology and cellular metabolism

• Multiple Sclerosis: potential focus areas include remyelination therapies and neuroprotection

• ALS and TDP-43 biology

Other Areas and Modalities | Include, but not limited to the following:

AI/Computational Approaches, Neurogenetics, Neuroimaging, Human-level data, Organoids and other complex cellular models.

For additional details on research areas of interest, please contact your campus ATN Alliance Manager using the contact information provided below.

• Projects should address important problems with high relevance to clinical or translational neuroscience and human health. Projects should lead to and describe tangible benefits to patients.

• Projects that incorporate ideas and/or research topics that may synergize with scientific expertise or capabilities at Roche/Genentech will be given priority.

• Projects should be relevant to the aims and research areas of the Weill Neurohub, including fostering collaborations between neuroscientists and researchers working in an array of disciplines – e.g., engineering, computer sciences, physics, chemistry, and mathematics – and across institutions.

• Projects that involve human subjects will require human research committee approval before funding is released.

Funding decisions will be based on scientific review by the ATN JSC and alignment of the proposal to the evaluation criteria. All applicants will be notified of final decisions.

The submission process will be comprised of three phases: initial Project Idea submissions, followed by Pre-Proposals, and Full Proposals.

Phase 1 | Project Idea Submissions

Applicants should submit a high-level Project Idea using the following form: https://airtable.com/appeCWZKkxk8BdBUM/pagOfvhN2ARfOngf0/form

The Project Idea form includes:

• Principal Investigator name and contact information

• Disease area and research area of interest

• Short description of a project idea for an ATN proposal (250 words or less)

• Relevant/recent published papers from your group

Project Idea Forms Due: February 5, 2026

Questions? A virtual information session will be held on January 22, 2026 at 2:00pm PT. If interested to attend, please contact your campus ATN Alliance Manager using the contact information provided below.

Phase 2 | Pre-Proposals

Selected applicants from Phase 1 will then be invited to submit a Pre-Proposal with a Roche/Genentech collaborator.

Pre-Proposals will require the following:

• Short 1-2 page submission

• Project Title, Academic Principal Investigator Name(s), Industry Principal Investigator Name, Background and Significance, Experimental Design and Methods, Estimated Budget, and Literature Cited (excluded from page limit).

• Clear scientific rationale and budget justification are essential. Projects with translational potential that fit within the budget guidelines will be prioritized.

Phase 3 | Full Proposals

Pre-proposals will be reviewed by the ATN JSC and selected projects will be invited to submit a Full Proposal.

• All Full Proposals must include joint scientific leads from both a Weill Neurohub-affiliated university and Roche and/or Genentech.

• Full Proposals will be reviewed by the ATN JSC and selected for funding.

Full Proposals will require the following:

• Background and Significance, Project Goals, Experimental Plan and Methods, Project Milestones and Timelines, Collaboration and Communication Plan.

• Other required items: Budget and Budget Justification, Literature Cited, Background IP, Third-Party Materials, Company Materials and Data Needed.

• All Full Proposals will require having a scientific co-lead from Roche/Genentech. Proposals will be reviewed based on Research Plan, Translational Potential, and ATN Alignment.